Below is a bookmarked list of the current clinical trials in the Minnesota Chapter area sorted by area. If you are interested in any of the trials, please contact the person listed for more information.
Mayo Clinic Rochester | Fargo | Minneapolis U of M | Minneapolis
|
Name of clinic |
University of Minnesota MS Center |
|
Name of trial |
TOWER |
|
Name of doctor |
Dr. Gareth Parry |
|
Purpose of study |
To evaluate the effectiveness of the investigational oral drug, teriflunomide at doses taken once daily compared to placebo in the treatment of MS. You may be eligible if you are aged 18-56 ,have a relapsing form of MS and have had at least one relapse in the past year or two relapses in the past 2 years. (An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA).) |
|
Contact |
Clinical Neuroscience Research Unit at U of M 612-626-5153 |
|
Name of clinic |
University of Minnesota MS Center |
|
Name of trial |
NAb |
|
Name of doctor |
Dr. Gareth Parry |
|
Purpose of study |
To determine whether adding oral steroids to Rebif improves the effectiveness of Rebif in treating relapsing-remitting multiple sclerosis. You may be eligible for this study if you have relapsing-remitting MS, have begun using Rebif in the past three months, and are aged 18 to 55. |
|
Contact |
Clinical Neuroscience Research Unit at U of M 612-624-6778 |
|
Minneapolis U of M |
|
|
Name of clinic |
University of Minnesota MS Center |
|
Name of trial |
Estriol |
|
Name of doctor |
Dr. Gareth Parry |
|
Purpose of study |
To determine whether adding oral estriol with Copaxone in treating women with relapsing-remitting multiple sclerosis will lessen relapse rates as compared to placebo. You may be eligible for this study if you have relapsing-remitting MS, able to walk without aids, had at least one relapse in the last two years, and are a woman aged 18 to 50. You are not eligible if you are pregnant, breast-feeding, smoke, or have other serious medical conditions. |
|
Contact |
Susan Rolandelli, U of M, 612-624-8431 |
|
Minneapolis U of M |
|
|
Name of clinic |
University of Minnesota MS Center |
|
Name of trial |
ADVANCE |
|
Name of doctor |
Dr. Gareth Parry |
|
Purpose of study |
To determine whether an investigational treatment is effective in preventing relapses in MS. You may be eligible if you have a diagnosis of relapsing-remitting MS, are aged 18-55, have had at least 2 relapses in the last 3 years and at least 1 occurrence in the past 12 months. |
|
Contact |
Clinical Neuroscience Research Unit at U of M 612-624-5153 |
|
Minneapolis U of M |
|
|
Name of clinic |
University of Minnesota MS Center |
|
Name of trial |
ORACLE |
|
Name of doctor |
Dr. Gareth Parry |
|
Purpose of study |
To study the efficacy, safety, and tolerability of oral cladribine tablets versus placebo in the treatment of CIS (Clinically Isolated Syndrome), and to evaluate the time to a potential conversion to clinically definite multiple sclerosis (CDMS). Additionally to evaluate the effects of cladribine versus placebo in regards to any disease progression in patients with CIS. |
|
Contact |
Clinical Neuroscience Research Unit at U of M 612-624-7745 |
|
Name of clinic |
Mayo Clinic |
|
Name of trial |
Aspirin Fatigue |
|
Name of doctor |
Dr. B Mark Keegan |
|
Purpose of study |
To study aspirin treatment for multiple sclerosis fatigue. You may be eligible if you are ambulatory without an aide, have had fatigue over eight weeks and are aged 18 to 65. |
|
Contact |
Darcy Rauchwarter, RN 507-284-9360 |
|
Name of clinic |
MeritCare MS Center |
|
Name of trial |
NAb |
|
Name of doctor |
Dr. Susan Scarberry |
|
Purpose of study |
To determine whether adding oral steroids to Rebif® improves the effectiveness of Rebif® in treating relapsing-remitting multiple sclerosis. You may be eligible for this study if you have relasping-remitting MS, have begun using Rebif® in the past 3 months, and are aged 18 to 55. |
|
Contact |
Tish Skarloken, 701-234-4091 |
|
Fargo |
|
|
Name of clinic |
MeritCare MS Center |
|
Name of trial |
ORACLE |
|
Name of doctor |
Dr. Susan Scarberry |
|
Purpose of study |
To study the efficacy, safety, and tolerability of oral cladribine tablets versus placebo in the treatment of CIS (Clinically Isolated Syndrome), and to evaluate the time to a potential conversion to clinically definite multiple sclerosis (CDMS). Additionally to evaluate the effects of cladribine versus placebo in regards to any disease progression in patients with CIS. |
|
Contact |
Tish Skarloken, 701-234-4091 |
|
Name of clinic |
MeritCare MS Center |
|
Name of trial |
DRI10566 |
|
Name of doctor |
Dr. Susan Scarberry |
|
Purpose of study |
To determine if an oral investigational drug is effective in improving ambulation in people with any form of multiple sclerosis. This 4 month trial is evaluating the effectiveness of 3 differnt doses versus a placebo. You may be eligible if you have clinically definite MS, are 18 years or older, not pregnant, have not had an exacerbation in the last 6 months and able to attend weekly clinic appointments. (An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA).) |
|
Contact |
Cheri Frisk, 701-234-4094 |
|
Name of clinic |
Multiplie Sclerosis Treatment & Research Center at the Minneapolis Clinic of Neurology |
|
Name of trial |
PM030 |
|
Name of doctor |
Dr. Gary Birnbaum |
|
Purpose of study |
To study the effects of glatiramer acetate (GA) on the retinal nerve fiber layer and visual function in people with a first episode of acute optic neuritis. You may be eligible if you are 18 – 45 years old and do not have a diagnosis of clinical definite MS |
|
Contact |
Nicole Goese, 763-302-4072 |